Rezolute (RZLT) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

RZLT · Stock Price

USD 3.09-0.61 (-16.49%)

Market Cap: $298.6M

Historical price data

Market Cap: $298.6MPipeline: 5 drugs (2 Phase 3)Founded: 2010HQ: Redwood City, United States

Sector Ranking#143 in Biologics / Biosimilars #64 in Rare & Orphan Diseases

Overview

Rezolute is a mission-driven, late-stage biotech dedicated to transforming the treatment landscape for hyperinsulinism (HI), a rare disease causing life-threatening hypoglycemia. Its lead asset, ersodetug, is a novel insulin receptor modulator with the potential to be a universal therapy across congenital and tumor-related HI forms. The company's strategy hinges on leveraging ersodetug's unique downstream mechanism and regulatory designations like Breakthrough Therapy to advance two Phase 3 registrational programs, aiming to deliver the first targeted therapy for hypoglycemia irrespective of its source.

Metabolic DisordersRare DiseasesEndocrinology

Technology Platform

A platform centered on ersodetug, a first-in-class, fully human monoclonal antibody that acts as an allosteric modulator of the insulin receptor to treat hypoglycemia caused by hyperinsulinism, offering a universal, downstream therapeutic approach.

Pipeline

5

5 drugs in pipeline2 in Phase 3

Drug	Indication	Stage
RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC + ...	Congenital Hyperinsulinism	Phase 3
Ersodetug	Tumor Hyperinsulinism (Tumor HI)	Phase 3
RZ358 Sequential Group Cohort 1 + RZ358 Sequential Group Coh...	Congenital Hyperinsulinism	Phase 2
Experimental: Group 1 - 50mg RZ402 + Experimental: Group 2 -...	Diabetic Macular Edema	Phase 2
Ersodetug (9 mg/kg) + SOC	Tumor-associated Hyperinsulinism (Tumor HI)	Pre-clinical

Opportunities

Rezolute's primary opportunity lies in establishing ersodetug as the first universal, disease-modifying therapy for life-threatening hypoglycemia across all forms of hyperinsulinism.

Success could unlock a high-value niche market, enable expansion into other hypoglycemia indications, and position the company as an attractive acquisition target for larger biopharma firms seeking rare disease assets.

Risk Factors

The company faces extreme binary risk centered on regulatory acceptance of its Phase 3 congenital HI data and the outcome of the ongoing tumor HI trial.

As a pre-revenue, single-asset company, any clinical or regulatory setback could necessitate highly dilutive financing or threaten corporate viability.

Competitive Landscape

Ersodetug operates in a space with limited effective therapies, facing competition primarily from decades-old, non-specific standard of care drugs (diazoxide, somatostatin analogs) and surgery. Its novel insulin receptor modulator mechanism appears first-in-class with no direct clinical-stage competitors, offering a significant potential differentiation if successfully developed.